TLDR UPS forecasts 2026 revenue of $89.7 billion, up from $88.7 billion in 2025, beating analyst expectations of $88.05 billion Fourth-quarter profit reached $1TLDR UPS forecasts 2026 revenue of $89.7 billion, up from $88.7 billion in 2025, beating analyst expectations of $88.05 billion Fourth-quarter profit reached $1

United Parcel Service (UPS) Stock Jumps on Earnings Beat and Revenue Outlook

2026/01/27 19:58
3 min read

TLDR

  • UPS forecasts 2026 revenue of $89.7 billion, up from $88.7 billion in 2025, beating analyst expectations of $88.05 billion
  • Fourth-quarter profit reached $1.79 billion ($2.10 per share), up from $1.72 billion ($2.01 per share) year-over-year
  • The company completed retirement of its MD-11 aircraft fleet during Q4, taking a $137 million write-off
  • UPS reduced workforce by 48,000 jobs last year and closed 93 facilities as part of restructuring efforts
  • Stock jumped 3.7% in premarket trading following the earnings announcement

UPS delivered better-than-expected earnings and an optimistic revenue forecast for 2026. The company is moving away from low-margin Amazon deliveries toward more profitable shipments.

The package delivery giant posted fourth-quarter profit of $1.79 billion, or $2.10 per share. That compares to $1.72 billion, or $2.01 per share, in the same period last year.

The quarter included $238 million in charges. The largest hit came from a $137 million write-off related to retiring the MD-11 aircraft fleet.


UPS Stock Card
United Parcel Service, Inc., UPS

UPS completed the MD-11 retirement during the fourth quarter. The decision followed a November crash of a 34-year-old MD-11 cargo plane that killed at least 12 people.

After removing one-time costs like the fleet write-off and roughly $100 million in restructuring charges, adjusted earnings hit $2.38 per share. Wall Street analysts had expected $2.20 per share.

Revenue fell 3.2% to $24.48 billion from $25.3 billion a year earlier. The figure still topped analyst estimates of $24.01 billion.

Strategic Shift Away from Amazon

The revenue decline reflects UPS’s deliberate strategy to reduce volumes from Amazon. The e-commerce giant was once the company’s largest customer.

CEO Carol Tomé called 2026 “an inflection point” as the Amazon transition wraps up. The company expects this shift to drive growth and margin expansion going forward.

UPS cut its workforce by approximately 48,000 positions last year. About 14,000 of those cuts were management roles.

The company closed daily operations at 93 leased and owned buildings. Automation has allowed UPS to operate with fewer facilities.

Looking Ahead to 2026

UPS expects 2026 revenue of approximately $89.7 billion. That beats the $88.05 billion analysts projected.

The company forecasts an adjusted operating margin of 9.6% for 2026. Capital expenditures are planned at around $3 billion.

UPS intends to pay approximately $5.4 billion in dividends, subject to board approval. The company will continue reviewing volume changes to identify more buildings for closure.

Shares rose 3.7% to $111.00 in premarket trading Tuesday. Rival FedEx gained about 1% during the same period.

The post United Parcel Service (UPS) Stock Jumps on Earnings Beat and Revenue Outlook appeared first on Blockonomi.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26